J Korean Med Sci.  2018 Feb;33(7):e55. 10.3346/jkms.2018.33.e55.

Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience

• Cho AR
• Yoon YH
• Kim JG
• Kim YJ
• Lee JY

• KMID: 2402997
• DOI: http://doi.org/10.3346/jkms.2018.33.e55

Abstract

BACKGROUND
The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy.
METHODS
A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015.
RESULTS
A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%). Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19-5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis.
CONCLUSION
Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent. Ophthalmological monitoring is required during chemotherapy.

Keyword

Chemotherapy; Cancer Chemotherapy Agents; Targeted Molecular Therapy; Drug Toxicity; Uveitis

MeSH Terms

Antineoplastic Agents
Breast Neoplasms
Cisplatin
Cytarabine
Daunorubicin
Diagnosis
Drug Therapy*
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Imatinib Mesylate
Molecular Targeted Therapy
Neoplasm Metastasis
Retrospective Studies
Tamoxifen
Toremifene
Uveitis
Uveitis, Anterior
Visual Acuity
Antineoplastic Agents
Cisplatin
Cytarabine
Daunorubicin
Imatinib Mesylate
Tamoxifen
Toremifene